Biomarker Core

生物标志物核心

• 批准号: 10668261
• 负责人: ADAM M BRICKMAN
• 金额: $ 34.91万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-15 至 2025-04-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10668261
• 关键词: APLP1 gene; Alzheimer' s Disease; Alzheimer' s disease related dementia; Alzheimer’s disease biomarker; Amyloid; Apolipoproteins; Biological; Biological Markers; Blood; Cerebrospinal Fluid; Cerebrovascular Disorders; Cholesterol Homeostasis; Classification Scheme; Clinical; Cognitive aging; Collaborations; Communities; Data; Data Sources; Data Store; Databases; Dementia; Detection; Development; Diagnostic; Disease; Endosomes; Etiology; Goals; Hemorrhage; Heterogeneity; Human; Immune response; Immunologic Markers; Infarction; Information Systems; International; Light; Liquid substance; MRI Scans; Magnetic Resonance Imaging; Measurement; Methods; Molecular; Nerve Degeneration; Participant; Pathway interactions; Plasma; Positron-Emission Tomography; Process; Protocols documentation; Radiology Specialty; Research; Research Personnel; Research Proposals; Resources; Scanning; Scientist; Secure; Sensitivity and Specificity; Standardization; Stream; Technology; Thick; Training; Universities; White Matter Hyperintensity; Work; brain magnetic resonance imaging; cerebrovascular; data exchange; exosome; imaging biomarker; improved; in vivo; instrumentation; interest; magnetic resonance imaging biomarker; neurofilament; neuroimaging; neuroimaging marker; next generation; novel; novel marker; participant enrollment; potential biomarker; programs; single molecule; sulfated glycoprotein 2; tau Proteins; trafficking; training opportunity

BIOMARKER CORE PROJECT SUMMARY/ABSTRACT The ability to study Alzheimer’s disease (AD) and related disorders has been revolutionized by the development and application of in vivo biomarkers. Analysis of cerebrospinal fluid (CSF), positron emission tomography (PET), and magnetic resonance imaging (MRI) allow operational measurement of amyloid, tau, and neurodegeneration (A/T/N), the major pathophysiological changes that define AD. Moreover, improved sensitivity and specificity of instrumentation applied to biofluid data, of neuroimaging protocols, and of analytic approaches both enable and necessitate the development, refinement, and discovery of novel biomarkers in any comprehensive AD research program. The Columbia University ADRC Biomarker Core embraces these theme and will derive standard biofluid and MRI biomarkers for all ADRC participants; serve as a central hub for human biofluid, PET, and MRI-based biomarker research conducted within the cognitive aging and dementia community at Columbia University; develop and implement novel biomarkers; and provide training opportunities for investigators interested in incorporating AD-related biomarkers into their research. The Biomarker Core leverages unique data sources, infrastructural, and intellectual strengths already in place and comprises a team of close-collaborating investigators instrumental to the majority of ongoing AD biomarker studies at Columbia University. The Biomarker Core will analyze research grade MRI scans acquired from harmonized clinical scans, from ongoing studies, or de novo for neurodegenerative and cerebrovascular markers. The Core features a newly-acquired single molecule array (Simoa) Benchtop Multiplexed Biomarker Detection Analyzer and Mesoscale Discovery (MSD) platform for analysis of CSF and blood and development of novel biomarkers. These resources will be used to derive existing blood- and CSF-based biomarkers and to develop novel ones. The deep biomarker characterization of all ADRC participants and close interaction with the other Cores will increase understanding of disease etiology and heterogeneity. The Biomarker Core has the following aims: 1) To harmonize, bank, and disseminate fluid and neuroimaging biomarker data derived from participants enrolled by the Clinical Core; 2) To quantitate biofluid biomarkers and MRI markers of neurodegeneration and cerebrovascular disease, according to the A/T/N classification scheme; 3) To develop, optimize, and implement biomarkers of the three thematic biological pathways: immune response, cholesterol metabolism, and endosomal trafficking; 4) To provide intellectual, analytic, and infrastructural support to local investigators interested in incorporating blood-based, CSF, MRI, and PET imaging biomarkers into their Alzheimer’s-related research programs; and 5) To provide training and training opportunities for the next generation of diverse scientists interested in incorporating biomarkers into the study of cognitive aging and dementia.

生物标记核心项目摘要/摘要 研究阿尔茨海默氏病 (AD) 及相关疾病的能力因技术的发展而发生了革命性的变化 脑脊液（CSF）、正电子发射断层扫描的体内生物标志物分析和应用。 (PET) 和磁共振成像 (MRI) 可以对淀粉样蛋白、tau 蛋白和 神经变性 (A/T/N)，定义 AD 的主要病理生理变化。 应用于生物流体数据、神经成像协议和分析的仪器的灵敏度和特异性 方法既能够实现也需要开发、完善和发现任何领域的新型生物标志物。 哥伦比亚大学 ADRC 生物标志物核心涵盖了这些主题。 并将为所有 ADRC 参与者提供标准生物流体和 MRI 生物标志物，作为人类的中心枢纽； 在认知衰老和痴呆症领域进行的生物流体、PET 和基于 MRI 的生物标志物研究 哥伦比亚大学；开发和实施新型生物标志物；并提供培训机会； 有兴趣将 AD 相关生物标志物纳入他们的研究的研究人员。 生物标记核心利用现有的独特数据源、基础设施和智力优势 并由一个密切合作的研究人员团队组成，对大多数正在进行的 AD 生物标志物发挥着重要作用 哥伦比亚大学的生物标记核心研究将分析从实验室获得的研究级 MRI 扫描。 协调一致的临床扫描，来自正在进行的研究，或从头开始用于神经退行性和脑血管 Core 采用新获得的单分子阵列 (Simoa) 台式多重生物标记物。 检测分析仪和 Mesoscale Discovery (MSD) 平台，用于分析脑脊液和血液及发育 这些资源将用于衍生现有的基于血液和脑脊液的生物标志物。 开发所有 ADRC 参与者的深入生物标志物特征并与他们密切互动。 其他核心将增加对疾病病因和异质性的了解。 以下目标： 1) 协调、存储和传播源自以下内容的体液和神经影像生物标志物数据： 临床核心招募的参与者；2) 定量生物体液生物标志物和 MRI 标志物 神经退行性疾病和脑血管疾病，根据 A/T/N 分类方案 3) 制定； 优化并实施三个主题生物途径的生物标志物：免疫反应、胆固醇 代谢和内体运输； 4) 为当地提供智力、分析和基础设施支持； 有兴趣将血液、脑脊液、MRI 和 PET 成像生物标志物纳入他们的研究中的研究人员 阿尔茨海默病相关的研究项目；以及 5) 为未来提供培训和培训机会 一代不同的科学家有兴趣将生物标志物纳入认知衰老的研究和 失智。